Spaulding Clinical Research — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Spaulding Clinical Research is a niche, technology-enabled CRO that has carved out a strong position in the high-stakes Phase I clinical trial market. By focusing exclusively on early-stage human pharmacology, the company offers deep expertise, a participant-centric facility, and integrated data systems designed to accelerate client timelines and improve data quality. Recent expansion into ADME trials and collaborations with regulatory bodies like the FDA indicate strategic growth and a reputation for scientific rigor. As a private company, it competes by providing a specialized, high-touch alternative to larger, full-service CROs in the critical first step of drug development.

Digital HealthClinical Research

Technology Platform

Integrated technology platform for clinical pharmacology, data management, and biometrics, featuring enhanced data collection, real-time monitoring, PK/PD modeling/simulation, and integrated EDC/CTMS systems to accelerate trial timelines and improve data quality.

Opportunities

Growth in outsourced Phase I trials and the expanding biopharmaceutical R&D pipeline, particularly for complex modalities, presents a steady demand stream.

Expansion into high-value specialty services like ADME studies allows for deeper client engagement and increased revenue per client.

Technological differentiation in data speed and quality can be a key competitive advantage in winning contracts from sponsors focused on development efficiency.

Risk Factors

Revenue is project-based and vulnerable to downturns in biopharma R&D funding and spending cycles.

The company faces intense competition from large, full-service CROs and other specialized Phase I units.

Operational risks include potential serious adverse events in trials, which could damage reputation and lead to regulatory action, impacting business continuity.

Competitive Landscape

Spaulding Clinical competes in the specialized Phase I CRO segment against large global CROs (e.g., IQVIA, LabCorp/Covance, Parexel) that offer broad services and against other dedicated Phase I units, both independent and academic. Its differentiation is based on deep niche expertise, a technology-integrated approach, and a client-centric, participant-focused facility, positioning it as an alternative to larger, potentially less specialized providers.

More companies in Digital Health & Biotech SaaS →More companies in United States →